CoChat

Discovery of a Highly Potent, Nonabsorbable Apical Sodium-Dependent Bile Acid Transporter Inhibitor (GSK2330672) for Treatment of Type 2 Diabetes

Open access
Wu, Yulin, Aquino, Christopher J., Cowan, David J., Anderson, Don L., Ambroso, Jeff L., Bishop, Michael J., Boros, Eric E., Chen, Lihong, Cunningham, Alan, Dobbins, Robert L., Feldman, Paul L., Harston, Lindsey T., Kaldor, Istvan W., Klein, Ryan, Liang, Xi, McIntyre, Maggie S., Merrill, Christine L., Patterson, Kristin M., Prescott, Judith S., Ray, John S., Roller, Shane G., Yao, Xiaozhou, Young, Andrew, Yuen, Josephine, Collins, Jon L. · 2013 · Journal of Medicinal Chemistry
Cited by 79

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

The apical sodium-dependent bile acid transporter (ASBT) transports bile salts from the lumen of the gastrointestinal (GI) tract to the liver via the portal vein. Multiple pharmaceutical companies have exploited the physiological link between ASBT and hepatic cholesterol metabolism, which led to the clinical investigation of ASBT inhibitors as lipid-lowering agents. While modest lipid effects were demonstrated, the potential utility of ASBT inhibitors for treatment of type 2 diabetes has been relatively unexplored. We initiated a lead optimization effort that focused on the identification of a potent, nonabsorbable ASBT inhibitor starting from the first-generation inhibitor 264W94 (1). Extensive SAR studies culminated in the discovery of GSK2330672 (56) as a highly potent, nonabsorbable ASBT inhibitor which lowers glucose in an animal model of type 2 diabetes and shows excellent developability properties for evaluating the potential therapeutic utility of a nonabsorbable ASBT inhibitor for treatment of patients with type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/jm400459m

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 79

Metadata

Authors
Wu, Y., Aquino, C. J., Cowan, D. J., Anderson, D. L., Ambroso, J. L., Bishop, M. J., Boros, E. E., Chen, L., Cunningham, A., Dobbins, R. L., Feldman, P. L., Harston, L. T., Kaldor, I. W., Klein, R., Liang, X., McIntyre, M. S., Merrill, C. L., Patterson, K. M., Prescott, J. S., Ray, J. S., Roller, S. G., Yao, X., Young, A., Yuen, J., & Collins, J. L.
Venue
Journal of Medicinal Chemistry
Published
2013-06-06
Volume
56
Issue
12
Pages
5094-5114
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W1979543957
Cited by
79
References
1
FWCI
2.37
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of a Highly Potent, Nonabsorbable Apical Sodium-Dependent Bile Acid Transporter Inhibitor (GSK2330672) for Treatment of Type 2 Diabetes. https://app.cochat.ai/papers/10.1021/jm400459m
The paper
Wu, Y., Aquino, C. J., Cowan, D. J., Anderson, D. L., Ambroso, J. L., Bishop, M. J., Boros, E. E., Chen, L., Cunningham, A., Dobbins, R. L., Feldman, P. L., Harston, L. T., Kaldor, I. W., Klein, R., Liang, X., McIntyre, M. S., Merrill, C. L., Patterson, K. M., Prescott, J. S., . . . Collins, J. L. (2013). Discovery of a Highly Potent, Nonabsorbable Apical Sodium-Dependent Bile Acid Transporter Inhibitor (GSK2330672) for Treatment of Type 2 Diabetes. Journal of Medicinal Chemistry. https://doi.org/10.1021/jm400459m

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.